Development of therapeutic strategies

Retroprion

Passive immunotherapy of prion disease

2007: 1 year / Grant: 35 000 euros

Project: As anti-PrP antibodies and dominant negative-PrP mutants have been reported to permanently cure prion-infected cells, and to delay prion disease in scrapie mouse models genetically modified or using viral vector systems to deliver these anti-prion molecules, the project proposed to test new vectors to express the anti-prion molecules for therapeutic purposes.

Main results and related published data: Several vector sytems and conditions were tested in this program to deliver anti-prion molecules. C. Zurzolo showed that lentiviralvectors used to express anti-PrP single chain variable fragment were more efficient than AAV (Adeno Associated Vectors) to transduce and reduce PrPTSE levels.

Development of antibody fragments for immunotherapy of prion diseases. Campana V1, Zentilin L, Mirabile I, Kranjc A, Casanova P, Giacca M, Prusiner SB, Legname G, Zurzolo C. Biochem J. 2009 Mar 15;418(3):507-15. doi: 10.1042/BJ20081541.